期刊
PEDIATRIC CLINICS OF NORTH AMERICA
卷 65, 期 4, 页码 757-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.pcl.2018.04.002
关键词
Juvenile localized scleroderma; Juvenile systemic sclerosis; Pediatric scleroderma; Morphea; Pediatric rheumatology; Extracutaneous involvement; Morbidity
类别
资金
- Bristol-Myers Squibb
- Childhood Arthritis and Rheumatology Research Alliance (CARRA)
- Arthritis Foundation
- Scleroderma Foundation
Scleroderma is a rare disease that has two main forms: localized scleroderma (LS) and systemic sclerosis (SSc). Both are chronic diseases, can present in different patterns (subtypes), and are associated with extracutaneous involvement in pediatric patients. Morbidity and mortality is much worse for juvenile SSc, with patients at risk for life-threatening lung, heart, and other visceral organ fibrosis and vasculopathy. Mortality is extremely rare in juvenile LS, but morbidity is common, with patients at risk for severe disfigurement and functional impairment. Scleroderma treatment is directed toward controlling inflammation and managing specific problems. Early diagnosis can greatly improve outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据